Mylan N.V. MYL is scheduled to report second-quarter 2016 results on Aug 9, after market close. Mylan’s performance has been impressive with the company beating earnings estimates in three of the last four quarters. Overall, the …
Eleven states require schools to stock epinephrine, according to Food Allergy Research & Education, an allergy advocacy group that counts Mylan as one of its corporate sponsors. A provision in the Federal Aviation Administration …
Mylan NV shares plummeted 9.2% in premarket trade Wednesday after the company reported profit and revenue misses and announced 2017 financial guidance that was below consensus. Earnings for the latest quarter rose to $297 million, …
PITTSBURGH – Generic drug maker Mylan Laboratories Inc. (MYL) is buying branded drug maker King Pharmaceuticals Inc. (KG) for about $4 billion in stock, company officials said Monday. Mylan has pursued a stronger position in the …
Through Thursday’s close, Mylan’s stock had lost about 37 percent of its value since it made public its offer to acquire Perrigo on April 8. Changes to Mylan stock price account for part of the change in total deal value. Following is a …
The company can also look forward to an FDA action date on November 13, 2018, …
Teva Pharmaceutical Industries, Ltd., has been trying to buy fellow giant generic drugmaker Mylan, Inc., and the latest step to emerge was the purchase of chunks of stock on the open market. Teva said it had bought a 1.35% stake in …
SmarTrend identified an Uptrend for Mylan Nv (NASDAQ:MYL) on September 12th, 2017 at $33.44. In approximately 4 months, Mylan Nv has returned 40.10% as of today's recent price of $46.85. In the past 52 weeks, shares of Mylan Nv …
Stringer, who manages the city’s five pension funds that own more than a million shares of Mylan stock worth $45 million, sent a letter to the company demanding corporate governance reform to boost oversight and accountability. The five city …
Mylan N.V. MYL is scheduled to report first-quarter 2017 results on May 10, before the market opens. The company’s performance has been mixed so far, having beaten earnings estimates in three of the trailing four quarters and missing …